GlassScriptPhysician profile
Pamela Manthous
NPI 1750389524
$1,028.16
in general payments reported to CMS, 2019-2025
19 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $852 · 2020: $98.52 · 2022: $16.26 · 2023: $43.49 · 2024: $17.99.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $61.48.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $61.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Duchesnay USA Incorporated | $156.25 | 2019 | |
| Abbvie INC. | $132.75 | 2019-2020 | |
| Therapeuticsmd, INC. | $132.50 | 2019-2020 | |
| Millicent US INC | $65.92 | 2019 | |
| Daiichi Sankyo INC. | $65.30 | 2019 | |
| Lupin INC. | $64.55 | 2019 | |
| Mylan Pharmaceuticals INC. | $55.89 | 2019-2020 | |
| Astellas Pharma US INC | $46.86 | 2019 | |
| Vertical Pharmaceuticals, LLC | $41.51 | 2019 | |
| Amgen INC. | $40.36 | 2023-2024 | Evenity, Prolia |
| Roche Diagnostics Corporation | $35.04 | 2019 | |
| Amag Pharmaceuticals, INC. | $31.46 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $31.29 | 2019-2020 | |
| Coopersurgical, INC. | $30.13 | 2019 | |
| Allergan, INC. | $24.16 | 2019 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $21.27 | 2019 | |
| Lilly USA, LLC | $21.12 | 2023 | Mounjaro |
| Currax Pharmaceuticals LLC | $16.26 | 2022 | |
| Exeltis, USA INC. | $15.54 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Pamela Manthous listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.